IRIDEX to Present at Upcoming Investor Conferences
Get Alerts IRIX Hot Sheet
Join SI Premium – FREE
MOUNTAIN VIEW, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in two upcoming investor conferences.
- November 9, 2017 at 1:30pm ET, IRIDEX’s management is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY
- November 14, 2017 at 9:30am ET, IRIDEX’s management is scheduled to present at the Stifel 2017 Healthcare Conference in New York, NY
Interested parties can access the live and archived webcasts at www.iridex.com.
About IRIDEXIRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations ContactLynn Pieper Lewis or Leigh Salvo(415) 937-5404[email protected]
Source: IRIDEX Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guelph Initiative Questions Whether OHIP Should Cover Psychotherapy
- Argument Introduces Structured AI Conflict Resolution App for Everyday Disputes
- CGX Energy Files June 30, 2026 Financial Statements and Announces Changes to the Board of Directors
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Stifel, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share